Hepatitis C (HCV) R&D Pipeline Analysis Report, Q4 2020
Hepatitis C (HCV) Pipeline Overview
The Q4 Hepatitis C (HCV) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Hepatitis C (HCV), provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Hepatitis C (HCV) Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Hepatitis C (HCV) disease overview, Hepatitis C (HCV) types, Hepatitis C (HCV) symptoms, causes, and FDA/EMA approved treatment options.
Hepatitis C (HCV) Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Hepatitis C (HCV) indication. The report presents near-term and long-term pipeline development trends and potential insights.
Hepatitis C (HCV) Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 63 companies. Business profiles and contact details of the companies actively perusing Hepatitis C (HCV) pipeline are assessed.
Hepatitis C (HCV) R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Hepatitis C (HCV) discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Hepatitis C (HCV) companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Hepatitis C (HCV) pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Hepatitis C (HCV) Pipeline Market News and Developments during 2020
The Hepatitis C (HCV) industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Hepatitis C (HCV) Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
The Q4 Hepatitis C (HCV) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Hepatitis C (HCV), provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Hepatitis C (HCV) Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Hepatitis C (HCV) disease overview, Hepatitis C (HCV) types, Hepatitis C (HCV) symptoms, causes, and FDA/EMA approved treatment options.
Hepatitis C (HCV) Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Hepatitis C (HCV) indication. The report presents near-term and long-term pipeline development trends and potential insights.
Hepatitis C (HCV) Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 63 companies. Business profiles and contact details of the companies actively perusing Hepatitis C (HCV) pipeline are assessed.
Hepatitis C (HCV) R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Hepatitis C (HCV) discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Hepatitis C (HCV) companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Hepatitis C (HCV) pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Hepatitis C (HCV) Pipeline Market News and Developments during 2020
The Hepatitis C (HCV) industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Hepatitis C (HCV) Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
- Hepatitis C (HCV) pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 63 companies are included including AB Pharma Ltd, AbbVie Inc, AIMM Therapeutics BV, Akshaya Bio Inc, Alla Chem LLC, Ascletis Pharma Inc, Atea Pharmaceuticals Inc, Beijing Kawin Technology Share-Holding Co Ltd, Beta Pharma Inc, Biotest Pharmaceuticals Corp, Biotron Ltd, Bolder Biotechnology Inc, Bristol-Myers Squibb Co, Cocrystal Pharma Inc, DEKK-TEC Inc, Dongguan HEC TaiGen Biopharmaceuticals Co Ltd, Ennaid Therapeutics LLC, F. Hoffmann-La Roche Ltd, FortuneRock (China) Ltd, Galactica Biotech Ltd, GeneCure LLC, Genoscience Pharma, Gilead Sciences Inc, GinkgoPharma Co Ltd, GlaxoSmithKline Plc, HEC Pharm Co Ltd, Hepion Pharmaceuticals Inc, ImmuneMed Inc, ImmunoBiology Ltd, Immunotope Inc, Inovio Pharmaceuticals Inc, Integrated BioTherapeutics Inc, iQur Ltd, J2H Biotech, Medivir AB, Merck & Co Inc, MetalloPharm LLC, Microbio Co Ltd, MultiCell Technologies Inc, Nanjing Sanhome Pharmaceutical Co Ltd, Nanogen Biopharmaceutical Co, Novalex Therapeutics Inc, Ono Pharmaceutical Co Ltd, PharmaEssentia Corp, Presidio Pharmaceuticals Inc, Profectus BioSciences Inc, Regulus Therapeutics Inc, Riboscience LLC, Rodos BioTarget GmbH, Savoy Pharmaceuticals Inc, Shanghai Newsummit Biopharma Co Ltd, Shanghai Tangrun Pharmaceuticals Co Ltd, Sino Biopharmaceutical Ltd, Sudershan Biotech Ltd, TaiGen Biotechnology Co Ltd, TGV Laboratories Inc, Therapure Biopharma Inc, THEVAX Genetics Vaccine USA Inc, Toray Industries Inc, Trek Therapeutics PBC, UBI Pharma Inc, Vertex Pharmaceuticals Inc, Virocovax,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in Hepatitis C (HCV) pipeline market
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
- Develop new candidates based on most focused targets and mechanism of actions
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. HEPATITIS C (HCV) PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Hepatitis C (HCV) Pipeline, 2020
2.2 Most focused Mechanism of Action in Hepatitis C (HCV) Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Hepatitis C (HCV) pipeline
2.5 Active Companies Developing Hepatitis C (HCV) pipeline
3. HEPATITIS C (HCV) DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. HEPATITIS C (HCV) PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 AB Pharma Ltd
AbbVie Inc
AIMM Therapeutics BV
Akshaya Bio Inc
Alla Chem LLC
Ascletis Pharma Inc
Atea Pharmaceuticals Inc
Beijing Kawin Technology Share-Holding Co Ltd
Beta Pharma Inc
Biotest Pharmaceuticals Corp
Biotron Ltd
Bolder Biotechnology Inc
Bristol-Myers Squibb Co
Cocrystal Pharma Inc
DEKK-TEC Inc
Dongguan HEC TaiGen Biopharmaceuticals Co Ltd
Ennaid Therapeutics LLC
F. Hoffmann-La Roche Ltd
FortuneRock (China) Ltd
Galactica Biotech Ltd
GeneCure LLC
Genoscience Pharma
Gilead Sciences Inc
GinkgoPharma Co Ltd
GlaxoSmithKline Plc
HEC Pharm Co Ltd
Hepion Pharmaceuticals Inc
ImmuneMed Inc
ImmunoBiology Ltd
Immunotope Inc
Inovio Pharmaceuticals Inc
Integrated BioTherapeutics Inc
iQur Ltd
J2H Biotech
Medivir AB
Merck & Co Inc
MetalloPharm LLC
Microbio Co Ltd
MultiCell Technologies Inc
Nanjing Sanhome Pharmaceutical Co Ltd
Nanogen Biopharmaceutical Co
Novalex Therapeutics Inc
Ono Pharmaceutical Co Ltd
PharmaEssentia Corp
Presidio Pharmaceuticals Inc
Profectus BioSciences Inc
Regulus Therapeutics Inc
Riboscience LLC
Rodos BioTarget GmbH
Savoy Pharmaceuticals Inc
Shanghai Newsummit Biopharma Co Ltd
Shanghai Tangrun Pharmaceuticals Co Ltd
Sino Biopharmaceutical Ltd
Sudershan Biotech Ltd
TaiGen Biotechnology Co Ltd
TGV Laboratories Inc
Therapure Biopharma Inc
THEVAX Genetics Vaccine USA Inc
Toray Industries Inc
Trek Therapeutics PBC
UBI Pharma Inc
Vertex Pharmaceuticals Inc
Virocovax
5. HEPATITIS C (HCV) PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. HEPATITIS C (HCV) PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2. HEPATITIS C (HCV) PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Hepatitis C (HCV) Pipeline, 2020
2.2 Most focused Mechanism of Action in Hepatitis C (HCV) Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Hepatitis C (HCV) pipeline
2.5 Active Companies Developing Hepatitis C (HCV) pipeline
3. HEPATITIS C (HCV) DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. HEPATITIS C (HCV) PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 AB Pharma Ltd
AbbVie Inc
AIMM Therapeutics BV
Akshaya Bio Inc
Alla Chem LLC
Ascletis Pharma Inc
Atea Pharmaceuticals Inc
Beijing Kawin Technology Share-Holding Co Ltd
Beta Pharma Inc
Biotest Pharmaceuticals Corp
Biotron Ltd
Bolder Biotechnology Inc
Bristol-Myers Squibb Co
Cocrystal Pharma Inc
DEKK-TEC Inc
Dongguan HEC TaiGen Biopharmaceuticals Co Ltd
Ennaid Therapeutics LLC
F. Hoffmann-La Roche Ltd
FortuneRock (China) Ltd
Galactica Biotech Ltd
GeneCure LLC
Genoscience Pharma
Gilead Sciences Inc
GinkgoPharma Co Ltd
GlaxoSmithKline Plc
HEC Pharm Co Ltd
Hepion Pharmaceuticals Inc
ImmuneMed Inc
ImmunoBiology Ltd
Immunotope Inc
Inovio Pharmaceuticals Inc
Integrated BioTherapeutics Inc
iQur Ltd
J2H Biotech
Medivir AB
Merck & Co Inc
MetalloPharm LLC
Microbio Co Ltd
MultiCell Technologies Inc
Nanjing Sanhome Pharmaceutical Co Ltd
Nanogen Biopharmaceutical Co
Novalex Therapeutics Inc
Ono Pharmaceutical Co Ltd
PharmaEssentia Corp
Presidio Pharmaceuticals Inc
Profectus BioSciences Inc
Regulus Therapeutics Inc
Riboscience LLC
Rodos BioTarget GmbH
Savoy Pharmaceuticals Inc
Shanghai Newsummit Biopharma Co Ltd
Shanghai Tangrun Pharmaceuticals Co Ltd
Sino Biopharmaceutical Ltd
Sudershan Biotech Ltd
TaiGen Biotechnology Co Ltd
TGV Laboratories Inc
Therapure Biopharma Inc
THEVAX Genetics Vaccine USA Inc
Toray Industries Inc
Trek Therapeutics PBC
UBI Pharma Inc
Vertex Pharmaceuticals Inc
Virocovax
5. HEPATITIS C (HCV) PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. HEPATITIS C (HCV) PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
